Margaret Lee
Director
Microbiology
Biotech Umea
Sweden
Biography
Margaret Lee joined Karyopharm Therapeutics in January 2015 bringing with her over 16 years of experience leading the discovery and translational development of novel drug candidates in multiple therapeutic areas including diabetes, infectious disease, oncology and CNS indications. Prior to joining Karyopharm, she was Vice President of Research and Translational Medicine at Zalicus Inc., where she led the discovery and development of multiple single agent and combination drug candidates including the demonstration of human proof of concept for a first in class T-type calcium channel modulator for the treatment of pain. Prior to joining Zalicus, she worked at the Aventis Pharmaceuticals Cambridge Genomics Center in Cambridge, MA. Margaret received her B.S. in Biology from Southampton College of Long Island University, her Ph.D. from Tufts University Sackler School and conducted her postdoctoral research in the laboratory of Dr. Pamela Silver at Harvard Medical School and Dana Farber Cancer Institute. She is a recognized international speaker and author on over 40 peer reviewed publications and patent families.
Research Interest
Microbiology
